Identifying harmful drug-protein interactions using advanced mass spectrometry techniques
Identification and quantification of drug-protein adducts by mass spectrometry
This study is looking at how some medications can unexpectedly cause problems by interacting with proteins in the body, and it aims to find out more about these interactions to help make medicines safer for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11099164 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain drugs can cause unexpected adverse reactions in patients by forming harmful complexes with proteins in the body. By using advanced mass spectrometry techniques, the researchers aim to identify and quantify these drug-protein adducts, which are often difficult to detect. The study will involve testing known drugs that have been associated with adverse events to better understand their mechanisms and improve drug safety. This work could lead to better predictions of drug safety and help in the development of safer medications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced adverse drug reactions or are taking medications known to form reactive metabolites.
Not a fit: Patients who are not currently taking medications or have not experienced any adverse drug reactions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly enhance drug safety by providing insights that prevent adverse drug reactions.
How similar studies have performed: Previous research has shown promise in using mass spectrometry for identifying drug-protein interactions, indicating that this approach could yield valuable insights.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Isoherranen, Nina — University of Washington
- Study coordinator: Isoherranen, Nina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.